Additionally, potential mutations were identified in the ctDNA of 51 patients with metastatic BC (including RB1, CDKN2A, and ERBB2), MAPK/ERK or PI3K/AKT/mTOR pathway-associated mutations, and chromatin remodeling-associated mutations [2]. Here, CDKN2A is linked to breast cancer.